Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AXXA should do a buyback with the profits to bring down the OS.
Ok...how about "priceless" mRNA drug developer...see below from the SBFM website:
Anticancer K1.1 mRNA
- K1.1 is an mRNA that encodes an inhibitor of a transcription factor essential for initiation of cell division
- We have recently shown that K1.1 mRNA is capable of destroying cancer cells in vitro including breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2)
- Tests conducted using non-transformed (normal) cells (HMEC) showed that these K1.1 mRNA had little cytotoxic effects
- K1.1 mRNA is readily adaptable for delivery into patients using the mRNA vaccine technology
- In April 2022, we filed a provisional patent application in the United States covering the K1.1 mRNA molecules and uses thereof
- Next, we plan to conduct mice xenograft studies to test the efficacy of K1.1 mRNA in vivo
Some more GREEN to $.02+ perhaps!
I don't think SBFM is a scam until they spend all the money they raised and don't produce any new drugs for a FDA approved clinical trial within the next 9-18 months. That is what the money was raised for (vs. lining their pockets) so we'll see which way this ends up sometime in 2023. Seems like a long way away, but a relatively short period to find out.
Also, from what I've read and heard, COVID treatments will be needed for years to come.
Right now the volume is generally low and the price has followed. Are you suggesting the volume will increase soon?
Why has CCAJ been so quiet since June 9th? They were very talkative on Twitter before that. Are they in a quiet period for some reason?
It is about time! Hopefully upward from now until 2023.
Did they mention a reverse split anywhere? As we all know those don't usually end well.
Some SBFM News would be nice! I'm not in a hurry here, but an update 1-2 times a month would be nice.
Anyone know when Pitre is going to move CCAJ up to the next level?
It is time for a SBFM Fireworks show...and time for an upward trend for the next 6-12 months. Time to go from $1 to $20+
Hopefully within weeks! Maybe in days, maybe in months, but anytime this year is good for me. I have a least 6 months of patience left on this one. Still buying here and there and then would like to see this Reddit Army in action on SBFM!
I think SBFM will be back to $4+ by the end of 2022 and $12+ by the end of 2023. I predict this will be based on progress related to both COVID and CANCER treatment drugs that we will hear more about in the coming months.
Although I was hoping the COVID pandemic was winding down, I keep reading about new variants that are evading current vaccines, thus getting more treatment options remains as important as ever.
No issues holding SBFM accountable to what they say they are doing and what there plan is for clinical trials. I think we'll get an update within the next 1-3 months and by then probably know if they will rise from the ashes or not. I think they will, but like all I'm waiting for the next update on COVID and CANCER treatments.
Don't forget they have a IR/PR firm and they are listed as a client. See TraDigital's website.
$.10 in 2022, $.20 in 2023 and $.40 in 2024 would be fine by me!
I speculate that SBFM will rise from the ashes over the next 6 months and 2023 will be the year of success! I picked up a few shares this week as part of my speculation.
I think within 3 months we'll get an update on the progress toward clinical trials. Within 12 months we'll know more about how close they are to market.
Ah. Just read it wrong then.
Are you saying that SBFM is on the SRO list only because of the vitamins?
Just doing some afternoon SBFM FDA browsing. I think we will know a lot more within 1-3 months.
So it looks like SBFM is a FDA SRO as defined below:
HHS Supplemental Standards of Ethical Conduct formally defines SRO as “an organization for which the sales of products regulated by the Food and Drug Administration (FDA) constitute ten percent or more of annual gross sales in the organization's previous fiscal year; where an organization does not have a record of sales of FDA-regulated products, it will be deemed to be significantly regulated if its operations are predominately in fields regulated by FDA, or if its research, development, or other business activities are reasonably expected to result in the development of products that are regulated by FDA."
Do you have a link to the ST messages regarding a buyback?
The share price is cheaper. Wouldn't that be a reason for anyone (including SBFM) to buy now.
Got the link for the IND Study...now just need the study launch date.
https://www.benzinga.com/general/biotech/22/05/27423151/sunshine-biopharma-prepares-for-ind-study-of-novel-cancer-drug-that-it-expects-could-beat-multidr
Can you post the link to this SBFM IND article?
So there will be some CCAJ fireworks after July 4th fireworks?
Let us know if they get back to you. The only good news for SBFM and myself is I plan to buy more if it hits $1.00. I didn't think it would go there so wasn't planning to buy anymore, but now I'm watching for that new low.
I think part of the issue here is their timeline for development is still months away so buying now may still bare fruit in 3-9 months. I'm not in a hurry to sell at this point.
Almost. It's been 10 years so far and only 12-18 months to go! Will you be hanging around long enough to see it?
SBFM's IR/PR firm (TraDigital) needs to get busy with a SBFM public information campaign including how they are spending the $18M+ they have for drug development.
TraDigital IR
917-633-8980
investors@sunshinebiopharma.com
https://tradigitalir.com/client/sunshine-biopharma-inc/
Midtermer...why don't you try this first...set up a meeting with management through TraDigital IR. Click the link below to set up meeting and let us know how it goes.
https://tradigitalir.com/meet-management/?company=Sunshine%20Biopharma,%20Inc.
Silence is sometimes golden, but I wonder what has happened in the SBFM world since their April 5th headline: "A Potential Multi-Billion Dollar Global Market Opportunity for Cancer Treatments"
Nice green uptick Friday. Will it continue on Monday?
Hope it hits $2.50 then $25 before $1.50.
Yes, so no money issues to take both drugs to market! They just need to pick up the pace on the cancer drug clinical trials at McGill U and the FDA fast track.
Will that Friday trading volume hint be today?
Acehole, was Moderna next door to SBFM anytime in the past 10 years? Moderna's move to the neighborhood where McGill U and SBFM are is a significant event for SBFM that can't be ignored!
Let's see...SBFM is a NASDAQ company, headquartered in Canada, where they just announced that Moderna is moving in to continue mRNA COVID work as well as work on other major illnesses in affiliation with McGill U which is where SBFM will conduct clinical trials for it's mRNA cancer drug.
Yes, the SBFM planets appear to be aligning and pointing to Montreal's McGill U as well as U of Arizona!
It is time for a series of PRs laying out the grand plan in more detail. Hopefully SBFM is done with financing the grand plan and can now accelerate delivery of the goods!
Thanks for the name: Dr. Gerald Batist, MD FACP
Deputy Director and Senior Investigator, Lady Davis Institute
Minda de Gunzburg Professor of Oncology, McGill University
Director, Segal Cancer Centre, Jewish General Hospital
Director, McGill Centre for Translational Research in Cancer, Lady Davis Institute
Dr. Batist's Publications Indexed on PubMed
Dr. Gerald Batist was Chairman of the Department of Oncology, McGill University from 2001 until 2011. He is Director of the McGill Centre for Translational Research in Cancer (MCTRC), which was established to stimulate rapid translation of new discoveries in the research laboratory into clinical benefits for patients. A major award from the Canada Foundation for Innovation allowed for the MCTRC to be expanded to create the Montreal Centre for Experimental Therapeutics in Cancer (MCETC), now a major component of the Segal Cancer Centre at the Jewish General Hospital, which also serves as the Experimental Therapeutics Axis of the Réseau de recherche sur le cancer of the Fonds de la recherche en santé du Québec (FRSQ). He is also Director of the Segal Cancer Centre.
In 2007, together with Dr. Luc Bélanger, Director of the Centre de recherche en cancérologie de l’Université Laval at l’ Hôtel Dieu de Quebec (CHUQ), Dr. Batist co-founded the Quebec – Clinical Research Organization in Cancer (Q-CROC), which focuses on biomarker-driven clinical trials and therapeutic resistance. It is also active in oncology care. Q-CROC operates as a network that brings together basic and clinician researchers, oncologists, surgeons and pathologists, among others. Its firm intention is to establish a province-wide translational and clinical research infrastructure in oncology.
Dr. Batist was born in Montreal. After beginning his university studies in New York City, he returned to attend medical school at McGill University. This was followed by post-doctoral training in New York, Boston, and, finally, at the National Cancer Institute in Washington, where he trained in medical oncology and molecular pharmacology.
Dr. Batist’s research programs are in novel therapeutics, and he’s made significant contributions to the development of new cancer treatments. In his capacity as Chairman of Oncology at McGill, he has nurtured the development of a number of multidisciplinary programs that have been highly innovative and are among the first of their kind in Canada. He leads a highly successful laboratory and clinical research program, which has been credited with over 180 scientific publications and a number of book chapters. He has trained many scientists and clinical oncologists, and also practices medical oncology.